Comparison of EMR versus endoscopic submucosal dissection for Barrett’s neoplasia and esophageal adenocarcinoma: A systematic review and meta-analysis

Background and aims: Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) are both accepted resection strategies for Barrett’s esophagus-related neoplasia and esophageal adenocarcinoma (EAC). However, a lack of consensus exists regarding which technique offers superior outcomes. This study aims to systematically review the evidence comparing EMR versus ESD in treating Barrett’s neoplasia and EAC.
Methods: The authors searched 3 databases (Embase, MEDLINE, Cochrane Central) through October 2023. They included studies comparing the efficacy of EMR and ESD for Barrett’s neoplasia and EAC. Primary outcomes include en bloc, R0, and curative resection; complete remission of dysplasia (CRD), and local recurrence. Secondary outcomes encompass adverse events.
Results: The search identified 905 records. Eleven studies were included in the final analyses. Data showed significantly higher en bloc resection rates with ESD (odds ratio [OR] = 31.53; 95% confidence interval [CI]: 10.02–99.19; p < 0.01; 7 studies). R0 resection rates were significantly higher with ESD (OR = 5.92; 95% CI: 2.75–12.77; p < 0.01; 8 studies). Curative resection rates tended to be higher with ESD (OR = 3.49; 95% CI: 0.86–14.14; p = 0.080; 4 studies). There was no significant difference in CRD rates (OR = 0.92; 95% CI: 0.37–2.26; p = 0.86; 3 studies). Local recurrence rates tended to be lower with ESD (OR = 0.35; 95% CI: 0.11–1.04; p = 0.058; 10 studies). As for adverse events, there was no significant difference in bleeding, perforation, and postoperative stricture rates.

Conclusions: This systematic review and meta-analysis demonstrates that endoscopic submucosal dissection (ESD) achieves higher en bloc, R0, and curative resection rates, with a tendency toward lower recurrence rates. These results suggest that ESD may be a more effective option for managing Barrett’s neoplasia and esophageal adenocarcinoma.

Y. Fujiyoshi, Division of Gastroenterology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada, E-Mail: yusukefujiyoshi@yahoo.co.jp

DOI: 10.1016/j.gie.2024.06.012

Back to overview

this could be of interest:

Preoperative chemoradiotherapy for resectable gastric cancer

N Engl J Med. 2024;391(19):1810-1821

Leong T, Smithers BM, Michael M, Haustermans K, Wong R, Gebski V, O’Connell RL, Zalcberg J, Boussioutas A, Findlay M, Willis D, Moore A, Murray WK, Lordick F, O’Callaghan C, Swallow C, Darling G, Miller D, Strickland A, Liberman M, Mineur L, Simes J; Australasian Gastro-Intestinal Trials Group, National Health and Medical Research Council Clinical Trials Centre, Trans-Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer, Canadian Cancer Trials Group

Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: Results from the European registry on H. pylori management (Hp-EuReg)

Gut. 2024;74(1):15-25

Olmedo L, Calvet X, Gené E, Bordin DS, Voynovan I, Castro-Fernandez M, Pabón-Carrasco M, Keco-Huerga A, Perez-Aisa Á, Lucendo AJ, Rodrigo L, Sarsenbaeva AS, Khlinov IB, Fadieienko G, Zaytsev O, Lanas Á, Martínez-Domínguez SJ, Alfaro E, Jonaitis L, Núñez Ó, Pellicano R, Hernández L, Gridnyev O, Kupcinskas J, Gasbarrini A, Boltin D, Niv Y, Babayeva G, Marcos-Pinto R, Tepes B, Venerito M, Papp V, Lerang F, Leja M, Phull PS, Marlicz W, Doulberis M, Smith SM, Milivojevic V, Kunovsky L, Mestrovic A, Matysiak-Budnik T, Simsek H, Cano-Català A, Puig I, Moreira L, Parra P, Nyssen OP, Megraud F, O’Morain C, Gisbert JP; Hp-EuReg investigators